Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 19 von 694
Peptides (New York, N.Y. : 1980), 1992-03, Vol.13 (2), p.401-407
1992
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists
Ist Teil von
  • Peptides (New York, N.Y. : 1980), 1992-03, Vol.13 (2), p.401-407
Ort / Verlag
New York, NY: Elsevier Inc
Erscheinungsjahr
1992
Quelle
ScienceDirect
Beschreibungen/Notizen
  • Small cell lung cancers (SCLC) synthesize and secrete bombesin/gastrin releasing peptide (BN/GRP). The autocrine growth cycle of BN/GRP in SCLC can be disrupted by BN/GRP receptor antagonists such as [Psi 13,14]BN. Here several BN analogues were solid-phase synthesized and incubated with intact SCLC cells at 37°C in RPMI medium in a time-course fashion (0–1080 minutes) to determine enzymatic stability. The proteolytic stability of the compounds was determined by subsequent HPLC analysis. The metabolic half-life ranged from 154 minutes to 1388 minutes for the six analogues studied. [Psi 13,14]BN was found to be very stable to metabolic enzymes ( T 1 2 = 646 mm ) and also inhibited SCLC xenograft formation in vivo in a dose-dependent manner. When [Psi 13,14]BN was incubated with NCI-H345 cells, it inhibited 125I-GRP binding with an IC 50 value of 30 nM. These data suggest that BN/GRP receptor antagonists such as [Psi 13,14]BN may be useful for the treatment of SCLC.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX